Advertisement
News
Subscribe to MDT Magazine News

Panama Canal Expansion is Fueling Key Trends for U.S. Supply Chains

June 1, 2011 12:35 pm | by Material Handling Industry of America | Comments

A recent White Paper by Jones Lang LaSalle identifies three major trends resulting from the 2014 Panama Canal expansion for U.S. companies to consider when evaluating their logistics and supply chain options. According to the paper titled "The Panama

SCAA Puts the 'AED' in CPR/AED Week to Make Communities Safer, Better Equipped to Respond to Cardiac Arrest

June 1, 2011 12:32 pm | by Bio-Medicine.Org | Comments

WASHINGTON, June 1, 2011 /PRNewswire-USNewswire/ -- For 30 years, the national survival rate of sudden cardiac arrest (SCA) has remained a low six percent. Recognizing the need for expanded awareness of the public health crisis of SCA, the Sudden Cardiac Arrest Association (SCAA) is...

TOPICS:

Letter To Foreign and Domestic Medical Device and Component Establishments That May Be Affected by the March 2011 Japan Earthquake and Tsunami

June 1, 2011 12:30 pm | by U.S. Food & Drug Administration | Comments

Japan is a critical participant in the global medical device market. As you know, on March 11, 2011, a massive earthquake and tsunami occurred near the northeastern coast of Japan, followed by various aftershocks, causing extensive damage to this region..

Advertisement

Information on Drugs of Abuse Tests (Updated)

June 1, 2011 12:30 pm | by U.S. Food & Drug Administration | Comments

FDA regulates and reviews drugs of abuse tests before they can be sold to consumers or healthcare professional in the United States. In its review, the FDA evaluates the design and performance of tests and sample collection systems to help ensure that...

TOPICS:

Claron Technology Makes the PROFIT 200 List for the Third Consecutive Year

June 1, 2011 11:35 am | by Bio-Medicine.Org | Comments

TORONTO, June 1, 2011 /- Claron Technology makes the PROFIT 200 list for the third consecutive year. Medical imaging software developer Claron Technology, headquartered in Toronto, has been included in the 23rd annual PROFIT 200 ranking of Canada's Fastest-Growing Companies by PROFIT...

TOPICS:

Beaumont Health System One of 14 Selected for National High Value Health Care Collaborative for High Quality Care at Lower Cost

June 1, 2011 11:35 am | by Bio-Medicine.Org | Comments

MACKINAC ISLAND, Mich., June 1, 2011 /- Beaumont Health System has been selected to join a prestigious national collaborative of health systems designed to improve health care quality, lower costs and expand best care practices to other health providers. Beaumont President and CEO Gene...

TOPICS:

Legs 4 Life, LLC Acquires Venosan North America

June 1, 2011 11:33 am | by Bio-Medicine.Org | Comments

ASHEBORO, N.C., June 1, 2011 /- Legs 4 Life, LLC, the parent company of Ames Walker International , proudly announced today that it has acquired Venosan North America, Venosan's American brand and distributorship of Venosan's Swiss made stockings.  The acquisition enables Legs 4 Life...

TOPICS:

Alexion lands FDA priority review for blood clotting drug target

June 1, 2011 10:33 am | by Mass High Tech: The Journal of New England Technology | Comments

Alexion Pharmaceuticals Inc. has won priority review from the U.S. Food and Drug Administration for its supplemental Biologics License Application for the company's drug candidate Soliris to treat atypical Hemolytic Uremic Syndrome.

TOPICS:
Advertisement

Repligen targets NDA for pancreatic imaging technology

June 1, 2011 9:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Repligen Corp. today said that it has concluded a pre-New Drug Application meeting with U.S. Food and Drug Administration officials regarding Repligen's technology for improving MRI views of the pancreas.

Sanofi restructuring Genzyme units

June 1, 2011 9:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Genzyme Corp., the subsidiary of French drug company Sanofi SA, will be restructured to trim down the Cambridge biotech's units, namely to retain just Genzyme's personalized genetic health and multiple sclerosis businesses, and integrate the others into existing Sanofi businesses.

EndoSphere Inc. Announces Pivotal Financing Led by Broadline Capital

June 1, 2011 9:34 am | by Bio-Medicine.Org | Comments

COLUMBUS, Ohio, June 1, 2011 /- EndoSphere Inc., a medical technology company developing a platform of endoscopically implantable devices for the treatment of metabolic diseases, including obesity and type 2 diabetes, announced today the completion of a highly oversubscribed Series A...

TOPICS:

Aegerion returns positive data for cholesterol treatment

June 1, 2011 8:36 am | by Mass High Tech: The Journal of New England Technology | Comments

Aegerion Pharmaceuticals, Inc., received positive data from a Phase 3 trial of its potential treatment for a rare genetic type of extremely high cholesterol, sending the company's stock up more than 4 percent.

New Study Questions Ability of Radiology Benefit Managers to Lower Costs

June 1, 2011 8:32 am | by Bio-Medicine.Org | Comments

WAUWATOSA, Wis., June 1, 2011 /PRNewswire-USNewswire/ -- The national policy debate on whether Radiology Benefit Managers (RBMs) should be required for physicians ordering diagnostic imaging tests for patients is analyzed in a new study appearing in the current issue of Journal of the...

TOPICS:

Brookdale will buy Horizon, form venture with HCP

June 1, 2011 7:45 am | by The Associated Press | Comments

Brookdale Senior Living Inc. said Wednesday it agreed to acquire senior living community operator Horizon Bay Realty, and will form a joint venture with HCP Inc. to manage some of those communities.The companies did not disclose financial terms of the Horizon Bay deal or the joint...

Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results

June 1, 2011 7:32 am | by Bio-Medicine.Org | Comments

HOBOKEN, N.J. and PHILADELPHIA, June 1, 2011 /- Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL. NKP-1339 is a novel transferrin...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading